Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$15.40
-2.9%
$12.67
$6.38
$16.66
$1.54B1.581.39 million shs1.46 million shs
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$7.15
$7.13
$1.08
$7.19
$373.81M1.661.70 million shsN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$24.05
-4.3%
$24.58
$21.97
$71.71
$1.51B2.84613,391 shs511,570 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.31
-1.2%
$30.52
$24.07
$55.33
$1.55B2.311.31 million shs1.50 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-2.90%-2.28%+11.84%+60.92%+12.82%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
0.00%0.00%0.00%0.00%+0.28%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-4.26%+0.29%-3.65%-3.41%-44.98%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.17%-1.75%-11.66%-24.49%-42.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$15.40
-2.9%
$12.67
$6.38
$16.66
$1.54B1.581.39 million shs1.46 million shs
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$7.15
$7.13
$1.08
$7.19
$373.81M1.661.70 million shsN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$24.05
-4.3%
$24.58
$21.97
$71.71
$1.51B2.84613,391 shs511,570 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.31
-1.2%
$30.52
$24.07
$55.33
$1.55B2.311.31 million shs1.50 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-2.90%-2.28%+11.84%+60.92%+12.82%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
0.00%0.00%0.00%0.00%+0.28%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-4.26%+0.29%-3.65%-3.41%-44.98%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.17%-1.75%-11.66%-24.49%-42.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.11
Buy$20.8635.44% Upside
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
0.00
N/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.07
Buy$80.92236.45% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4095.18% Upside

Current Analyst Ratings Breakdown

Latest GTHX, TWST, JANX, and AVDL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/10/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
9/5/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$24.00 ➝ $36.00
9/3/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$72.00
9/3/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/3/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$72.00
9/2/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageEqual Weight$16.00
8/21/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $20.00
8/18/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$42.00
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M8.84N/AN/A$0.77 per share20.00
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$58.20M6.42N/AN/A$0.68 per share10.51
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10.59M136.47N/AN/A$19.49 per share1.23
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$362.27M4.22N/AN/A$8.07 per share3.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.03N/A256.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)

Latest GTHX, TWST, JANX, and AVDL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$0.02$0.10+$0.08$0.10$60.28 million$68.13 million
8/7/2025Q2 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.79
2.38
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
1.34
2.48
2.12
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
47.03
47.03
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
24.21%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
6.11%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7097.10 million92.05 millionOptionable
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
17052.28 million49.09 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3060.09 million55.23 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Twist Bioscience (NASDAQ:TWST) Sets New 1-Year Low on Insider Selling
Twist Bioscience (NASDAQ:TWST) Trading Down 5.4% - What's Next?
Invesco Small Cap Growth Fund Q2 2025 Commentary
Twist Bioscience Collaborates with Synthetic Design Lab

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$15.40 -0.46 (-2.90%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$15.15 -0.25 (-1.62%)
As of 09/12/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

G1 Therapeutics stock logo

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$24.05 -1.07 (-4.26%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$24.13 +0.08 (+0.33%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$25.31 -0.30 (-1.17%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$25.58 +0.27 (+1.05%)
As of 09/12/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.